in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Sorrento to acquire antibody-drug conjugation technology
12:43 PM MST | November 14, 2013 | Deepti Ramesh
Sorrento Therapeutics (San Diego), a publicly traded, development-stage biopharmaceutical company, says it has entered into a definitive agreement to acquire Concortis Biosystems (San Diego) in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody-drug conjugates (ADCs). Sorrento, under the terms of the agreement, will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. This acquisition will enable Sorrento to utilize the antibodies identified from its G-MAB library along with...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee